Remdesivir

Remdesivir
Clinical data
Pronunciation	/rɛmˈdɛsɪvɪər/ rem-DESS-i-veer
Synonyms	GS-5734
AHFS/Drugs.com	Professional Drug Facts
Routes of; administration	Intravenous
ATC code	None;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (2S)-2-{(2R,3S,4R,5R)-[5-(4-Aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]phenoxy-(S)-phosphorylamino}propionic acid 2-ethyl-butyl ester;
CAS Number	1809249-37-3 ;
PubChem CID	121304016;
DrugBank	DB14761 ;
ChemSpider	58827832;
UNII	3QKI37EEHE;
KEGG	D11472;
ChEBI	CHEBI:145994;
ChEMBL	ChEMBL4065616;
ECHA InfoCard	100.302.974
Chemical and physical data
Formula	C27H35N6O8P
Molar mass	602.58 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(COC(=O)[C@@H](NP(=O)(Oc1ccccc1)OC[C@H]1O[C@@]([C@@H]([C@@H]1O)O)(C#N)c1ccc2n1ncnc2N)C)CC;
	InChI InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1; Key:RWWYLEGWBNMMLJ-YSOARWBDSA-N;

Remdesivir is a broad-spectrum antiviral medication created by the biopharmaceutical company Gilead Sciences.^[1] It was designed to treat Ebola.

As of 2020, remdesivir is being tested as a specific treatment for COVID-19. It is being used for the sickest of patients during the pandemic.^[2] It may shorten the time it takes to recover from the infection.^[3] Treatment is given by injection into a vein.^[4]^[5]

On May 1, the United States Food and Drug Administration gave doctors permission to use remdesivir on patients with COVID-19. Ordinarily, the FDA would test remdesivir first to see if it worked on patients with COVID-19, but because of the COVID-19 pandemic, they told doctors they could start using the drug before the tests were finished.

In October 2020, the National Institutes of Health told the world the results of its tests. They studied 11,000 people and found that remdesivir did not help keep COVID-19 patients alive. Gilead and some scientists said the results of the tests might not be correct.^[6]

References[change | change source]

↑ Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. (April 2020). "Current pharmacological treatments for COVID-19: what's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. PMC 7264618. PMID 32329520.
↑ "Remdesivir EUA Letter of Authorization" (PDF). U.S. Food and Drug Administration (FDA). 1 May 2020. Retrieved 1 May 2020.
↑ Kolata G, Baker P, Weiland N (29 April 2020). "Remdesivir Shows Modest Benefits in Coronavirus Trial". The New York Times. Retrieved 3 May 2020.
↑ "Remdesivir". Drugs.com. Retrieved 30 April 2020.
↑ Mehta N, Mazer-Amirshahi M, Alkindi N (April 2020). "Pharmacotherapy in COVID-19; A narrative review for emergency providers". The American Journal of Emergency Medicine. 38 (7): S0735-6757(20)30263-1. doi:10.1016/j.ajem.2020.04.035. PMC 7158837. PMID 32336586. Archived from the original on 2020-05-02. Retrieved 2020-05-05.
↑ Gina Kolata; Katherine J. Wu (October 15, 2020). "Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial". New York Times. Retrieved October 21, 2020.

This short article about medicine can be made longer. You can help Wikipedia by adding to it.

[Scavone_2020-1] Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. (April 2020). "Current pharmacological treatments for COVID-19: what's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. PMC 7264618. PMID 32329520.

[FDA_EUA-2] "Remdesivir EUA Letter of Authorization" (PDF). U.S. Food and Drug Administration (FDA). 1 May 2020. Retrieved 1 May 2020.

[3] Kolata G, Baker P, Weiland N (29 April 2020). "Remdesivir Shows Modest Benefits in Coronavirus Trial". The New York Times. Retrieved 3 May 2020.

[4] "Remdesivir". Drugs.com. Retrieved 30 April 2020.

[Mehta2020-5] Mehta N, Mazer-Amirshahi M, Alkindi N (April 2020). "Pharmacotherapy in COVID-19; A narrative review for emergency providers". The American Journal of Emergency Medicine. 38 (7): S0735-6757(20)30263-1. doi:10.1016/j.ajem.2020.04.035. PMC 7158837. PMID 32336586. Archived from the original on 2020-05-02. Retrieved 2020-05-05.

[NYTFail-6] Gina Kolata; Katherine J. Wu (October 15, 2020). "Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial". New York Times. Retrieved October 21, 2020.

[1]

[2]

[3]

[4]

[5]

[6]